Applicant, as named in the Orange Book

Janssen Pharms

Next listed expiry: Invokamet Xr on 26 Aug 2029. 8 products with live protection, 10 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Invokamet Xr · 4 strengths canagliflozin; metformin hydrochloride	canagliflozin; metformin hydrochloride	205879	26 Aug 2029	patent
Invokana · 2 strengths canagliflozin	canagliflozin	204042	26 Aug 2029	patent
Invokamet · 4 strengths canagliflozin; metformin hydrochloride	canagliflozin; metformin hydrochloride	204353	6 Jul 2030	patent
Invega Sustenna · 5 strengths paliperidone palmitate	paliperidone palmitate	022264	26 Jan 2031	patent, carve-out possible
Xarelto · 4 strengths rivaroxaban	rivaroxaban	022406	17 Aug 2034	patent
Invega Trinza · 4 strengths paliperidone palmitate	paliperidone palmitate	207946	5 Apr 2036	patent, carve-out possible
Spravato esketamine hydrochloride	esketamine hydrochloride	211243	18 Feb 2040	patent, carve-out possible
Invega Hafyera · 2 strengths paliperidone palmitate	paliperidone palmitate	207946	24 Nov 2041	patent, carve-out possible

Recent events

25 Oct 2026Ortho Tri-Cyclen · Generic approved 23 Sep 2026
25 Oct 2026Invega · Generic approved 26 Jan 2026
25 Oct 2026Xarelto · Generic approved 14 Nov 2025
25 Oct 2026Xarelto · Generic approved 2 Mar 2026
25 Oct 2026Xarelto · Generic approved 7 Oct 2025
25 Oct 2026Xarelto · Generic approved 24 Oct 2025
25 Oct 2026Ortho Tri-Cyclen Lo · Generic approved 23 Sep 2026
25 Oct 2026Xarelto · Generic approved 1 Jul 2026
25 Oct 2026Invokana · First generic approved 14 Apr 2026
25 Oct 2026Invokana · Generic approved 14 Apr 2026
25 Oct 2026Invokana · Generic tentatively approved 21 Jul 2026
25 Oct 2026Xarelto · Generic approved 19 Aug 2026
25 Oct 2026Invega · Generic approved 7 May 2026
25 Oct 2026Xarelto · Generic approved 20 Feb 2026
25 Oct 2026Invokana · Generic tentatively approved 29 Sep 2025
25 Oct 2026Xarelto · Generic approved 25 Sep 2025
25 Oct 2026Xarelto · Generic approved 30 Jun 2026
25 Oct 2026Invokana · Generic approved 20 Apr 2026

Products without listed protection (10)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Concerta · 4 strengths methylphenidate hydrochloride	methylphenidate hydrochloride	021121	open now	no listed protection
Elmiron pentosan polysulfate sodium	pentosan polysulfate sodium	020193	open now	no listed protection
Invega · 3 strengths paliperidone	paliperidone	021999	open now	no listed protection
Risperdal · 6 strengths risperidone	risperidone	020272	open now	no listed protection
Risperdal risperidone	risperidone	020588	open now	no listed protection
Risperdal Consta · 4 strengths risperidone	risperidone	021346	open now	no listed protection
Sporanox itraconazole	itraconazole	020083	open now	no listed protection
Topamax · 4 strengths topiramate	topiramate	020505	open now	no listed protection
Topamax · 2 strengths topiramate	topiramate	020844	open now	no listed protection
Xarelto rivaroxaban	rivaroxaban	215859	open now	no listed protection